JP2002524509A - 新規組成物 - Google Patents

新規組成物

Info

Publication number
JP2002524509A
JP2002524509A JP2000569803A JP2000569803A JP2002524509A JP 2002524509 A JP2002524509 A JP 2002524509A JP 2000569803 A JP2000569803 A JP 2000569803A JP 2000569803 A JP2000569803 A JP 2000569803A JP 2002524509 A JP2002524509 A JP 2002524509A
Authority
JP
Japan
Prior art keywords
component
treatment
composition
pharmaceutical preparation
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000569803A
Other languages
English (en)
Japanese (ja)
Inventor
ジョン・エヴァンデン
セト−ウーロフ・トールベルイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2002524509A publication Critical patent/JP2002524509A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2000569803A 1998-09-16 1999-09-13 新規組成物 Pending JP2002524509A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9803157A SE9803157D0 (sv) 1998-09-16 1998-09-16 A new composition
SE9803157-8 1998-09-16
PCT/SE1999/001598 WO2000015219A1 (en) 1998-09-16 1999-09-13 A new composition

Publications (1)

Publication Number Publication Date
JP2002524509A true JP2002524509A (ja) 2002-08-06

Family

ID=20412628

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000569803A Pending JP2002524509A (ja) 1998-09-16 1999-09-13 新規組成物

Country Status (21)

Country Link
EP (1) EP1121119A1 (ko)
JP (1) JP2002524509A (ko)
KR (1) KR20010099648A (ko)
CN (1) CN1317963A (ko)
AR (1) AR023657A1 (ko)
AU (1) AU6378199A (ko)
BR (1) BR9913765A (ko)
CA (1) CA2342585A1 (ko)
CZ (1) CZ2001962A3 (ko)
EE (1) EE200100156A (ko)
HU (1) HUP0103569A3 (ko)
ID (1) ID28359A (ko)
IL (1) IL141520A0 (ko)
IS (1) IS5877A (ko)
NO (1) NO20011313L (ko)
PL (1) PL346769A1 (ko)
SE (1) SE9803157D0 (ko)
SK (1) SK3272001A3 (ko)
TR (1) TR200100769T2 (ko)
WO (1) WO2000015219A1 (ko)
ZA (1) ZA200101951B (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR021155A1 (es) 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
DE60122015T2 (de) 2000-10-13 2006-11-23 Neurosearch A/S Behandlung affektiver störungen durch kombinierte wirkung eines nikotinischen rezeptoragonisten und einer monoaminergischen substanz
WO2006038217A1 (en) * 2004-10-05 2006-04-13 Strides Acrolab Limited An improved drug delivery system of citalopram hydrobromide and process for producing the same
WO2006123243A2 (en) 2005-05-20 2006-11-23 Aurobindo Pharma Limited Pharmaceutical dosage forms comprising escitalopram in form of granules
TW200812993A (en) * 2006-05-02 2008-03-16 Lundbeck & Co As H New uses of escitalopram

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9501567D0 (sv) * 1995-04-27 1995-04-27 Astra Ab A new combination

Also Published As

Publication number Publication date
KR20010099648A (ko) 2001-11-09
TR200100769T2 (tr) 2001-11-21
EE200100156A (et) 2002-08-15
HUP0103569A3 (en) 2002-03-28
SE9803157D0 (sv) 1998-09-16
PL346769A1 (en) 2002-02-25
IS5877A (is) 2001-03-05
CN1317963A (zh) 2001-10-17
AU6378199A (en) 2000-04-03
ZA200101951B (en) 2002-06-10
NO20011313L (no) 2001-05-16
NO20011313D0 (no) 2001-03-15
ID28359A (id) 2001-05-17
HUP0103569A2 (hu) 2002-02-28
BR9913765A (pt) 2001-06-05
CA2342585A1 (en) 2000-03-23
AR023657A1 (es) 2002-09-04
IL141520A0 (en) 2002-03-10
WO2000015219A1 (en) 2000-03-23
EP1121119A1 (en) 2001-08-08
CZ2001962A3 (cs) 2001-08-15
SK3272001A3 (en) 2001-09-11

Similar Documents

Publication Publication Date Title
TWI298255B (en) Use of optically pure (s.s)-reboxetine in the manufacture of a medicament for the treatment or prevention of fibromyalgia or another somatoform disorder
US6184218B1 (en) Composition and methods employing it for the treatment of 5-HT-mediated disorders
JP2008531714A (ja) 不安障害の治療用及び／又は予防用の医薬組成物
JPH083035A (ja) 医薬の応答反応の増強
JP2002515435A (ja) 鬱病処置のための組合せ治療
JP2005505539A (ja) パーキンソン病の治療のためのｃｂ１受容体アンタゴニストと、脳のドーパミン作用性神経伝達を活性化する製品を含む組成物
JP2002511414A (ja) 神経疾患のための新しい治療
US6472423B1 (en) Pharmaceutical composition
JP2002524509A (ja) 新規組成物
JP2002524510A (ja) 新規組成物
JP2002524507A (ja) 新規組成物
JP2002511408A (ja) 神経疾患のための新しい治療
JP2002524508A (ja) 新規組成物
MXPA01002543A (en) A new composition
WO2007112065A2 (en) Methods for treating cognitive and other disorders
MXPA01002370A (en) A new composition